Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 52 mg intrauterine system (IUS) for intrauterine use. It works by preventing fertilization and implantation, providing long‑term contraception, and is also employed off‑label to reduce heavy menstrual bleeding in reproductive‑age women.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide in accordance with EU regulatory standards and ensuring quality assurance throughout the supply chain. The company adheres to stringent quality management systems and provides regulatory documentation to support import and clinical use.

Kyleena, a levonorgestrel‑based intrauterine system, is used within the hormonal contraceptive pathway to prevent pregnancy and manage menstrual disorders.

- Contraception: provides a highly effective, reversible method for preventing pregnancy for up to five years. - Heavy menstrual bleeding: reduces menstrual blood loss and may improve anemia in women with excessive bleeding. - Long‑acting reversible contraception: offers continuous hormone release, eliminating the need for daily dosing and enhancing adherence.

Levonorgestrel IUS may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal cramping - Breast tenderness - Mood changes - Headache

Serious or Rare Side Effects: - Uterine perforation during insertion - IUS expulsion or displacement - Pelvic inflammatory infection - Ectopic pregnancy if contraception fails - Allergic reaction or hypersensitivity - Ovarian cyst formation

Prior to insertion of Kyleena, clinicians should observe several precautionary measures to ensure patient safety and device effectiveness.

- Confirm non‑pregnancy: verify the patient is not pregnant before placement. - Evaluate uterine anatomy: avoid use in known uterine anomalies or fibroids that distort the cavity. - Treat existing infections: resolve pelvic or cervical infections prior to insertion. - Review concomitant medications: consider drugs that may affect hormonal activity. - Counsel on bleeding changes: inform patients about possible irregular bleeding patterns. - Store at room temperature: keep the device in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Kyleena can interact with other medicines, influencing its contraceptive efficacy or safety.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce levonorgestrel levels. - Antifungal azoles (e.g., ketoconazole, itraconazole): can increase systemic exposure and risk of side effects. - Protease inhibitors used in HIV therapy: potential for altered hormone metabolism.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly diminish contraceptive effectiveness. - Herbal supplements such as St. John’s wort: may reduce hormone levels. - Combined hormonal therapies (e.g., estrogen patches): may modify bleeding patterns and require monitoring.